tirzepatide shortage ending FDA Zepbound ends, impacts patients, compounding pharmacies FDA Ends Tirzepatide Shortage (Compounded

Originally used to treat diabetes, this GLP-1 receptor agonist has proven its effectiveness in promoting weight loss as a side effect

The visual inspection takes seconds

Bottom Line Diarrhea affects roughly one in five people taking tirzepatide, but it is usually mild, temporary, and manageable

Since the medication already slows gastric emptying, consuming large meals can overwhelm the digestive system's reduced capacity

Brand-name Mounjaro and Zepbound pens function this way

GLP-1 Diet Plan Tips: Although this guide is centered around Tirzepatide, many of the dietary strategies apply broadly to GLP-1 medications as a whole